Resistance to MEK Inhibitors: Should We Co-Target Upstream?

Sci. Signal., 29 March 2011
Vol. 4, Issue 166, p. pe16
DOI: 10.1126/scisignal.2001948

Resistance to MEK Inhibitors: Should We Co-Target Upstream?

  1. Poulikos I. Poulikakos1 and
  2. David B. Solit2,3,*
  1. 1Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
  2. 2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
  3. 3Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
  1. *Corresponding author. Telephone, 646-888-2641; e-mail, solitd{at}


Aberrant activation of the ERK pathway is common in human tumors. This pathway consists of a three-tiered kinase module [comprising the kinases RAF, mitogen-activated protein kinase (MAPK) kinase (MEK), and extracellular signal–regulated kinase (ERK)] that functions as a negative feedback amplifier to confer robustness and stabilization of pathway output. Because this pathway is frequently dysregulated in human cancers, intense efforts are under way to develop selective inhibitors of the ERK pathway as anticancer drugs. Although promising results have been reported in early trials for inhibitors of RAF or MEK, resistance invariably occurs. Amplification of the upstream oncogenic driver of ERK signaling has been identified as a mechanism for MEK inhibitor resistance in cells with mutant BRAF or KRAS. Increased abundance of the oncogenic driver (either KRAS or BRAF in the appropriate cellular context) in response to prolonged drug treatment results in increased flux through the ERK pathway and restoration of ERK activity above the threshold required for cell growth. For patients with BRAF mutant tumors, the results suggest that the addition of a RAF inhibitor to a MEK inhibitor may delay or overcome drug resistance. The data thus provide a mechanistic basis for ongoing trials testing concurrent treatment with RAF and MEK inhibitors.


P. I. Poulikakos and D. B. Solit, Resistance to MEK Inhibitors: Should We Co-Target Upstream?. Sci. Signal. 4, pe16 (2011).

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
R. Chakraborty, O. A. Hampton, X. Shen, S. J. Simko, A. Shih, H. Abhyankar, K. P. H. Lim, K. R. Covington, L. Trevino, N. Dewal et al.
Blood 124, 3007-3015 (6 November 2014)

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells
G. Ambrosini, R. Khanin, R. D. Carvajal, and G. K. Schwartz
Molecular Cancer Therapeutics 13, 2073-2080 (1 August 2014)

Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling
M. Schoumacher, K. E. Hurov, J. Lehar, Y. Yan-Neale, Y. Mishina, D. Sonkin, J. M. Korn, D. Flemming, M. D. Jones, B. Antonakos et al.
Cancer Res. 74, 3294-3305 (15 June 2014)

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
M. H. Nissan, C. A. Pratilas, A. M. Jones, R. Ramirez, H. Won, C. Liu, S. Tiwari, L. Kong, A. J. Hanrahan, Z. Yao et al.
Cancer Res. 74, 2340-2350 (15 April 2014)

Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
A. Nakamura, T. Arita, S. Tsuchiya, J. Donelan, J. Chouitar, E. Carideo, K. Galvin, M. Okaniwa, T. Ishikawa, S. Yoshida et al.
Cancer Res. 73, 7043-7055 (1 December 2013)

Network-based drug discovery by integrating systems biology and computational technologies
E. L. Leung, Z.-W. Cao, Z.-H. Jiang, H. Zhou, and L. Liu
Brief Bioinform 14, 491-505 (1 July 2013)

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
N. Tan, M. Wong, M. A. Nannini, R. Hong, L. B. Lee, S. Price, K. Williams, P. P. Savy, P. Yue, D. Sampath et al.
Molecular Cancer Therapeutics 12, 853-864 (1 June 2013)

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
T. A. Yap, A. Omlin, and J. S. de Bono
JCO 31, 1592-1605 (20 April 2013)

Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission
D. van der Hoeven, K.-j. Cho, X. Ma, S. Chigurupati, R. G. Parton, and J. F. Hancock
Mol. Cell. Biol. 33, 237-251 (15 January 2013)

Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy
N. Rath, and M. F. Olson
EMBO Rep. 13, 900-908 (1 October 2012)

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
H. Wong, L. Vernillet, A. Peterson, J. A. Ware, L. Lee, J.-F. Martini, P. Yu, C. Li, G. D. Rosario, E. F. Choo et al.
Clin. Cancer Res. 18, 3090-3099 (1 June 2012)

Computational Approaches for Analyzing Information Flow in Biological Networks
B. Kholodenko, M. B. Yaffe, and W. Kolch
Sci Signal 5, re1-re1 (17 April 2012)

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882